STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

View/ Open
Published Version
https://doi.org/10.1186/2051-1426-1-S1-P175Metadata
Show full item recordCitation
Srivastava, Raghvendra M, Hyun-bae Jie, Soldano Ferrone, and Robert L Ferris. 2013. “STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P175. doi:10.1186/2051-1426-1-S1-P175. http://dx.doi.org/10.1186/2051-1426-1-S1-P175.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991086/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407007
Collections
- HMS Scholarly Articles [17730]
Contact administrator regarding this item (to report mistakes or request changes)